Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
KZR
Kezar Life Sciences, Inc.
Kezar’s AIH program targets a liver disease indication, fitting the Liver Disease Therapeutics theme.
|
$45.40M |
$6.24
-4.00%
|
|
GTHP
Guided Therapeutics, Inc.
LuViva is a point-of-care diagnostic device used for cervical cancer screening, which aligns with Diagnostic Equipment.
|
$45.14M |
$0.43
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$43.91M |
$3.58
|
|
TELO
Telomir Pharmaceuticals, Inc. Common Stock
Telomir-1 is described as an oral small molecule therapeutic candidate, directly matching the 'Oral Small Molecule Therapeutics' tag.
|
$43.90M |
$1.36
-4.23%
|
|
NMTC
NeuroOne Medical Technologies Corporation
Core product category: neuromodulation devices used to treat epilepsy and pain via brain stimulation and ablation.
|
$43.80M |
$0.89
+0.21%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's pipeline centers on neuropsychiatric drug development (NRX-100, NRX-101) targeting suicidal depression and bipolar depression.
|
$43.75M |
$2.20
-5.58%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$43.41M |
$7.93
+5.31%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Actinium directly develops radiopharmaceutical therapies using alpha-emitting isotopes (Ac-225) for oncology (ATNM-400, Actimab-A, Iomab-ACT).
|
$43.36M |
$1.40
-2.10%
|
|
TELA
TELA Bio, Inc.
TELA Bio manufactures OviTex Reinforced Tissue Matrix, a medical device/biomaterial used in soft tissue reconstruction, aligning with Medical Devices & Biometrics.
|
$43.18M |
$1.09
|
|
CTSO
Cytosorbents Corporation
CytoSorbents' core offering is the CytoSorb blood purification device used in ICU and cardiac surgery to remove inflammatory mediators and toxins.
|
$42.90M |
$0.61
-10.18%
|
|
ECOR
electroCore, Inc.
Directly markets and sells neuromodulation medical devices (gammaCore, Quell, Truvaga, Sparrow Ascent, TAC-STIM).
|
$42.69M |
$5.54
+10.24%
|
|
ACET
Adicet Bio, Inc.
Directly develops allogeneic cell therapies (gamma delta T cells) for autoimmune diseases and cancer as its primary product platform.
|
$41.78M |
$8.04
-0.56%
|
|
ICCM
IceCure Medical Ltd
IceCure manufactures liquid nitrogen-based cryoablation medical devices (ProSense/XSEN) used for tumor destruction, i.e., medical devices & biometrics.
|
$41.69M |
$0.72
+2.01%
|
|
MDAI
Spectral AI, Inc.
DeepView is a diagnostic imaging device used to detect and manage wounds, fitting Diagnostic Equipment.
|
$41.17M |
$1.53
-3.46%
|
|
LHSW
Lianhe Sowell International Group Ltd Ordinary Shares
Exploration into medical applications via machine vision implies Medical Devices & Biometrics relevance.
|
$40.56M |
$0.76
+1.99%
|
|
PRPO
Precipio, Inc.
Pathology/clinical lab services and diagnostic testing operations.
|
$40.12M |
$24.00
+3.95%
|
|
BDSX
Biodesix, Inc.
Biodesix's Nodify and VeriStrat are blood-based diagnostic tests, i.e., liquid biopsy products.
|
$40.03M |
$5.38
-3.49%
|
|
SABS
SAB Biotherapeutics, Inc.
Company focuses on immunology therapeutics using DiversitAb platform to generate fully human polyclonal antibodies.
|
$39.67M |
$3.81
+5.99%
|
|
INMB
INmune Bio, Inc.
Directly represents INmune Bio's Alzheimer's disease therapeutics focus under the XPro DN-TNF program.
|
$39.61M |
$1.50
-2.29%
|
|
FGEN
FibroGen, Inc.
FibroGen's FG-3246 is an oncology-focused therapeutic program, making Biotech - Oncology a core investment theme.
|
$39.28M |
$9.53
+5.60%
|
|
ZJYL
Jin Medical International Ltd.
The company designs, manufactures, and sells rehabilitation medical devices and biometrics-oriented equipment.
|
$38.76M |
$0.26
-2.58%
|
|
ETST
Earth Science Tech, Inc.
ETST's core pharmaceutical operations include compounding pharmacies (RxCompound, Mister Meds) providing outsourced drug manufacturing services.
|
$38.25M |
$0.13
|
|
XLO
Xilio Therapeutics, Inc.
Xilio is a clinical-stage biotechnology company focused on oncology therapies, placing it in Biotech - Oncology.
|
$37.95M |
$0.73
+0.33%
|
|
LTRN
Lantern Pharma Inc.
Lantern is a biotech company with a focused oncology pipeline and programs.
|
$37.69M |
$3.48
+2.80%
|
|
ATHE
Alterity Therapeutics Limited
ATH434 is a small-molecule oral therapeutic in clinical development (Phase 2) for neurodegenerative disease, identified as Alterity's lead product.
|
$37.46M |
$3.50
+5.11%
|
|
MYO
Myomo, Inc.
MyoPro is a prosthetic upper-limb device designed to replace or assist movement for partially paralyzed limbs, fitting Prosthetics & Implants.
|
$37.36M |
$0.99
+1.49%
|
|
SKYE
Skye Bioscience, Inc.
Nimacimab is a monoclonal antibody therapeutic targeting CB1, making Monoclonal Antibody Therapeutics the direct product category.
|
$37.19M |
$1.20
-0.42%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$37.05M |
$0.57
+1.43%
|
|
JUNS
Jupiter Neurosciences, Inc.
Alzheimer's Disease Therapeutics: Pipeline consideration includes cognitive impairment/early Alzheimer's indications.
|
$36.92M |
$1.03
+0.49%
|
Showing page 29 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
